Companies here have a ticker and primary exchange in their Clari profile. The set grows as we add new case studies. It is not a complete screener of all US-listed life sciences issuers.
Listings are curated case studies on Clari, not a complete directory of the cluster or of all public issuers. Pipeline text is for product demonstration; verify on ClinicalTrials.gov and official filings. Not medical or investment advice.
Watertown, MA, USA
Kymera Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation (TPD) to develop a new generation of small-molecule therapies for immune-inflammatory and oncology diseases. Using its proprietary Pegasus™ platform, Kymera designs bifunctional degrader molecules that use the cell's own proteasome machinery to selectively eliminate disease-causing proteins, including historically undruggable targets such as transcription factors.
Boston, MA, USA
Vertex Pharmaceuticals is a global biotechnology company focused on discovering, developing, and producing transformative medicines for people with serious diseases. Vertex dominates the cystic fibrosis market with five approved CFTR modulators (including Trikafta and ALYFTREK) and is diversifying into pain (JOURNAVX), gene editing (CASGEVY with CRISPR Therapeutics), cell therapy (zimislecel for type 1 diabetes), kidney disease (povetacicept for IgAN, inaxaplin for APOL1), and neuromuscular disease (VX-670 for myotonic dystrophy).